LM-108 is under clinical development by LaNova Medicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LM-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LM-108 is under development for the treatment of advanced solid tumors. The drug candidate is administered through intravenous route. It acts by targeting C-C Chemokine Receptor Type 8.
LaNova Medicines overview
LaNova Medicines (LaNova) focuses on therapeutic projects from antibody discovery. LaNova is headquartered in Shanghai, China.
For a complete picture of LM-108’s drug-specific PTSR and LoA scores, buy the report here.